Overview

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Status:
Completed

Trial end date:
2002-11-01

Target enrollment:

Participant gender:

Summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Diphosphonates
Zoledronic Acid